Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Nature medicine · 2023
    MAManish A Shah
    PMID: 37524953PMCID: PMC10427418DOIFirst author729 citations
  2. 2
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    MAManish A Shah
    PMID: 38954176PMCID: PMC11335819DOISenior author97 citations
  3. 3
    Future oncology (London, England) · 2021
    MAManish A Shah
    PMID: 33533655PMCID: PMC7927908DOIFirst author144 citations

Publications

263 publications

Funding

11 grantsView NIH portfolio on RePORTER ↗

Active

4 grants
  • Co-I
    PICI Grant and Main Collaboration Agreement with Multiple Subprojects
    Parker Institute for Cancer Immunotherapy · 2024–2028
    PICI 235170-03
  • PI
    Development and application of an artificial intelligence (AI) foundation model for somatic variants in cancer
    The Asco Cancer Foundation · 2026–2027
    ASCO 253887-01
  • Co-I
    Clinical and Translational Science Center - UL1
    National Center for Advancing Translational Sciences · 2017–2027· 2 renewals
    UL1TR002384-06
  • Sub-PI
    The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network
    National Cancer Institute · 2021–2027 · via The Ohio State University· 2 renewals
    UM1CA186712-09
Completed grants (7)
  • MPI
    A novel, short isoform of the +TIP microtubule (MT) binding protein CLIP170 confers taxane resistance by obstructing the MT pore.
    National Cancer Institute · 2018–2024
    R01CA228512-05
  • Sub-PI
    Targeting Genomic, Metabolic and Immunological Vulnerabilities of Colorectal Cancer
    American Association for Cancer Research · 2017–2024 · via Sloan-Kettering Institute for Cancer Research
    SU2C-AACR-DT22-17
  • Co-I
    Communicating the Gist of Prognosis: Giving Information Simply and Transparently ("GIST") in Advanced Cancer
    National Institute of Nursing Research · 2019–2022
    R21NR018693-02
  • KP
    Use of Mobile Applications to Evaluate Post Surgical Recovery in Aging Patients with GI Cancer
    Damon Runyon Cancer Research Foundation · 2019–2022
    DRCRF 89C-16
  • PI
    Imaging and targeting glycolytically driven oxidative stress using ascorbate
    Starr Cancer Consortium · 2019–2022
    I12-0031
  • PI
    The Impact of the Gastric Microbiome on Gastric Cancer Development
    Starr Cancer Consortium · 2015–2018
    I8-A8-132
  • PI
    Phase 2 Irinotecan for Treatment of p53 WT Gastric Adenocarcinoma
    NIH · 2010–2013 · via NIH RePORTER
    R01FD003755-03

Clinical research

28 studies

Active

7 studies
  • PI
    A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)
    PHASE3 · AstraZeneca, PLC · OPEN TO ACCRUAL (as of 2026)
    Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer
    NCT07431281
  • PI
    A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
    PHASE2 · Gilead Sciences, Inc. · OPEN TO ACCRUAL (as of 2026)
    HER2-negative; Gastroesophageal Junction; Esophageal Adenocarcinoma; Gastric Adenocarcinoma
    NCT07546812
  • PI
    A Phase1 b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors
    PHASE1; PHASE2 · GlaxoSmithKline · OPEN TO ACCRUAL (as of 2026)
    Gastrointestinal Neoplasms
    NCT06885034
  • PI
    A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)
    PHASE3 · AstraZeneca, PLC · OPEN TO ACCRUAL (as of 2025)
    HER2-positive Gastric Cancer; Gastroesophageal Junction Adenocarcinoma
    NCT06764875
  • PI
    Phase II Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in PD-L1-Negative or Immunotherapy-refractory Esophagogastric Adenocarcinoma
    PHASE2 · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
    Esophageal Adenocarcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
    NCT06340711
  • PI
    Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
    PHASE2 · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
    Colorectal Cancer Metastatic; Liver Metastases; Colorectal Cancer
    NCT06300463
  • PI
    Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma
    PHASE3 · Alliance for Clinical Trials in Oncology · OPEN TO ACCRUAL (as of 2024)
    Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Unresectable Esophageal Adenocarcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma
    NCT05677490
Completed & closed trials (21)
  • PI
    A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma.
    PHASE3 · Merck Sharp & Dohme Corp · IRB STUDY CLOSURE (as of 2025)
    Metastatic Esophageal Squamous Cell Carcinoma
    NCT04949256
  • PI
    An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
    PHASE1 · AMAL Therapeutics · IRB STUDY CLOSURE (as of 2025)
    Colorectal Cancer; MSS; Stage IV Colon Cancer; Stage IV Rectal Cancer; Metastatic Colorectal Cancer; Liver Metastasis Colon Cancer
    NCT04046445
  • PI
    A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
    PHASE3 · Southwest Oncology Group · IRB STUDY CLOSURE (as of 2025)
    Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
    NCT03768414
  • PI
    Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer
    PHASE3 · The General Hospital Corporation (dba Massachusetts General Hospital) · CLOSED TO ACCRUAL (as of 2025)
    Metastatic Colon Cancer; Stage III Colon Cancer
    NCT03803553
  • PI
    A Multi-site, Open-label, Phase II, Randomized, Controlled Trial to Compare the Efficacy of RO7198457 Versus Watchful Waiting in Resected, Stage II (High Risk) and Stage III Colorectal Cancer Patients Who Are ctDNA Positive Following Resection
    PHASE2 · BioNTech SE · IRB STUDY CLOSURE (as of 2024)
    Colorectal Cancer Stage II; Colorectal Cancer Stage III
    NCT04486378
  • PI
    Prospective Evaluation of Nivolumab in Adjuvant Esophageal Carcinoma/Gastroesophageal Junction Carcinoma: A Non-interventional Study
    Bristol-Myers Squibb Company · IRB STUDY CLOSURE (as of 2024)
    Esophageal Carcinoma; Gastroesophageal Junction Carcinoma
    NCT05780736
  • PI
    A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
    PHASE1; PHASE2 · NousCom SRL · CLOSED TO ACCRUAL (as of 2024)
    Solid Tumor, Adult
    NCT04041310
  • PI
    Novel Exploratory Study to Test Combination of Botensilimab and Balstilimab Immunotherapy in Resectable Colorectal Cancer Patients
    PHASE2 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2024)
    Colorectal Neoplasms
    NCT05571293
  • PI
    A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination With Chemotherapy and/or Immunotherapy in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma Whose Are Claudin (CLDN) 18.2 Positive
    PHASE2 · Astellas Pharma Inc. · IRB STUDY CLOSURE (as of 2024)
    Pharmacokinetics of Zolbetuximab; Gastric Cancer; Gastro-esophageal Junction (GEJ) Cancer; Pharmacokinetics of Oxaliplatin; Pharmacokinetics of Fluorouracil Bolus (5-FU)
    NCT03505320
  • PI
    A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
    PHASE3 · Merck Sharp & Dohme Corp · CLOSED TO ACCRUAL (as of 2024)
    Esophageal Squamous Cell Carcinoma (ESCC); Gastroesophageal Junction Carcinoma (GEJC); Esophageal Adenocarcinoma (EAC)
    NCT04210115
  • PI
    Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
    PHASE2 · Seattle Genetics, Inc. · IRB STUDY CLOSURE (as of 2024)
    Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous; Non-small Cell Lung Cancer, Non-squamous; Head and Neck Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Prostate Cancer; Melanoma
    NCT04032704
  • PI
    A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
    PHASE3 · F. Hoffman La-Roche Ltd · IRB STUDY CLOSURE (as of 2023)
    Esophageal Squamous Cell Carcinoma
    NCT04543617
  • PI
    A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
    PHASE3 · Astellas Pharma Global Development, Inc. · IRB STUDY CLOSURE (as of 2023)
    Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
    NCT03653507
  • PI
    A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination With Balstilimab (AGEN2034) or Investigator's Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer
    PHASE2 · Agenus Inc · CLOSED TO ACCRUAL (as of 2023)
    Metastatic Colorectal Cancer
    NCT05608044
  • PI
    A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
    PHASE2 · National Cancer Institute · IRB STUDY CLOSURE (as of 2023)
    Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma
    NCT03641313
  • PI
    Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
    PHASE2 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2023)
    Gastroesophageal Adenocarcinoma
    NCT04021108
  • PI
    A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
    PHASE2; PHASE3 · ECOG-ACRIN Cancer Research Group · CLOSED TO ACCRUAL (as of 2022)
    Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
    NCT03604991
  • PI
    Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
    PHASE3 · Alliance for Clinical Trials in Oncology · CLOSED TO ACCRUAL (as of 2022)
    Colorectal Adenocarcinoma
    NCT04094688
  • PI
    Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
    PHASE1; PHASE2 · Vedanta Biosciences, Inc. · IRB STUDY CLOSURE (as of 2022)
    Metastatic Cancer; Melanoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Colorectal Cancer
    NCT04208958
  • PI
    A Phase 2, Multicenter Open-label, Non-randomized Study of Bavituximab Plus Pembrolizumab in Patients With Advanced Gastric or Gastroesophageal Cancer Who Have Progressed on or After at Least One Prior Standard Therapy
    PHASE2 · Oncologie, Inc. · IRB STUDY CLOSURE (as of 2022)
    Gastric Cancer; GastroEsophageal Cancer
    NCT04099641
  • PI
    A Phase 2, Open-label, Single-arm Trial of Trastuzumab Deruxtecan (DS 8201a) in HER2-positive, Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-containing Regimen (DESTINY-Gastric02)
    PHASE2 · Daiichi Sankyo, Inc. · IRB STUDY CLOSURE (as of 2021)
    Adenocarcinoma Gastric Stage IV With Metastases; Adenocarcinoma - GEJ
    NCT04014075

News mentions

2 mentionsView all WCM news ↗
  • A New Targeted Treatment Shows Promise for Select Patients with Stomach Cancer
    August 23, 2023

    An international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker.

  • Key Immune Cells Maintain Healthy Gut Bacteria to Protect Against Colorectal Cancer
    August 17, 2021

    An immune cell subset called innate lymphoid cells (ILC3s) protects against colorectal cancer, in part by helping to maintain a healthy dialogue between the immune system and gut microbes, according to a new study led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.

Media highlights

3 clips

Mentoring

1 mentee